|
Futura Medical PLC - Guildford, Surrey-based sexual health products - Shares rise 4.5% on Wednesday as Futura reports positive results from a ’sensory’ study of its WSD4000 treatment for sexual dysfunction in women. Futura explains that a sensory study assesses how healthy volunteers perceive product characteristics through their senses. The study involved 67 women with some degree of sexual dysfunction, and WSD4000 produced a positive change in a majority of them after four weeks. ‘Following the success of the study, alongside market research on the size of the opportunity following commercialisation, the board is recommending to proceed with an early feasibility study during H1 2025,’ Futura says. Head of R&D Ken James adds: ‘We believe that female sexual health is an underserved market and under discussed problem where women are needlessly suffering in silence with unsatisfactory options available to them.’ Futura’s lead product is Eroxon, which treats erectile dysfunction in males, and has a US distribution agreement in place for this with consumer health products firm Haleon PLC. Current stock price: 32.02 pence, up 1.6% on Thursday in London 12-month change: down 1.5% Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
